Gossamer Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 226,604,138 | $23 | $1,296,848 | $(1,268,568) | $1,189 | $29,492 |
| Exercise of stock options | 112,617 | — | 132 | — | — | 132 |
| Stock-based compensation | — | — | 2,405 | — | — | 2,405 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 504,507 | — | 372 | — | — | 372 |
| Net loss | — | — | — | (36,638) | — | (36,638) |
| Other comprehensive loss | — | — | — | — | (2,013) | (2,013) |
| Balance as of March 31, 2025 | 227,221,262 | $23 | $1,299,757 | $(1,305,206) | $(824) | $(6,250) |
| Exercise of stock options | 101,266 | — | 94 | — | — | 94 |
| Stock-based compensation | — | — | 2,586 | — | — | 2,586 |
| Net loss | — | — | — | (38,273) | — | (38,273) |
| Other comprehensive loss | — | — | — | — | (4,264) | (4,264) |
| Balance as of June 30, 2025 | 227,322,528 | $23 | $1,302,437 | $(1,343,479) | $(5,088) | $(46,107) |
| Investment in merger option through issuance of stock | 2,500,000 | 1 | 7,475 | — | — | 7,476 |
| Exercise of stock options | 438,351 | — | 465 | — | — | 465 |
| Exercise of warrants | 459,870 | — | 938 | — | — | 938 |
| Stock-based compensation | — | — | 2,666 | — | — | 2,666 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 585,376 | — | 469 | — | — | 469 |
| Net loss | — | — | — | (48,221) | — | (48,221) |
| Other comprehensive loss | — | — | — | — | (19) | (19) |
| Balance as of September 30, 2025 | 231,306,125 | $24 | $1,314,450 | $(1,391,700) | $(5,107) | $(82,333) |
| Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2023 | 225,409,315 | $23 | $1,275,136 | $(1,212,040) | $(350) | $62,769 |
| Stock-based compensation | — | — | 5,811 | — | — | 5,811 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 390,246 | — | 348 | — | — | 348 |
| Issuance of common stock for restricted stock units vested | 419,092 | — | — | — | — | — |
| Net loss | — | — | — | (41,928) | — | (41,928) |
| Other comprehensive loss | — | — | — | — | (278) | (278) |
| Balance as of March 31, 2024 | 226,218,653 | $23 | $1,281,295 | $(1,253,968) | $(628) | $26,722 |
| Stock-based compensation | — | — | 5,001 | — | — | 5,001 |
| Issuance of common stock for restricted stock units vested | 8,606 | — | — | — | — | — |
| Grant of equity option pursuant to Chiesi Collaboration Agreement | — | — | 464 | — | — | 464 |
| Net income | — | — | — | 49,232 | — | 49,232 |
| Other comprehensive income | — | — | — | — | 110 | 110 |
| Balance as of June 30, 2024 | 226,227,259 | $23 | $1,286,760 | $(1,204,736) | $(518) | $81,529 |
| Stock-based compensation | — | — | 4,842 | — | — | 4,842 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 376,879 | — | 281 | — | — | 281 |
| Net loss | — | — | — | (30,803) | — | (30,803) |
| Other comprehensive loss | — | — | — | — | (1,713) | (1,713) |
| Balance as of September 30, 2024 | 226,604,138 | $23 | $1,291,883 | $(1,235,539) | $(2,231) | $54,136 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.